Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Hepatology International · 2023
DOI: 10.1007/s12072-023-10491-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology International, 2023. Verfasst von Mathew Vithayathil und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Institute of Helath Research, European Association for the Study of the Liver.
Abstract (Originalsprache)
Background
Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC.
Methods
191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated.
Results
Patients in the overweight cohort ( n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort ( n = 97). Baseline Child–Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2% vs. 22.0%; p = 0.44) and DCR (74.1% vs. 71.9%; p = 0.46). There were higher rates of atezolizumab-related fatigue (22.3% vs. 10.3%; p = 0.02) and bevacizumab-related thrombosis (8.5% vs. 2.1%; p = 0.045) in the overweight patients, but overall trAEs and treatment discontinuation were comparable between cohorts.
Conclusion
Atezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
- Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Förderung
- Wellcome Trust
- National Institute of Helath Research
- European Association for the Study of the Liver
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Vithayathil, M., D'Alessio, A., Fulgenzi, C. A. M., Nishida, N., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Saeed, A., Wietharn, B., Hildebrand, H., Wu, L., Ang, C., Marron, T. U., Weinmann, A., Galle, P. R., Bettinger, D., Bengsch, B., Vogel, A., …, & Sharma, R. (2023). Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatology International. https://doi.org/10.1007/s12072-023-10491-3
Vancouver
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, et al. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatology International. 2023. doi:10.1007/s12072-023-10491-3
BibTeX
@article{Vithayathil2023,
author = {Vithayathil, Mathew and D'Alessio, Antonio and Fulgenzi, Claudia Angela Maria and Nishida, Naoshi and Schönlein, Martin and von Felden, Johann and Schulze, Kornelius and Wege, Henning and Saeed, Anwaar and Wietharn, Brooke and Hildebrand, Hannah and Wu, Linda and Ang, Celina and Marron, Thomas U and Weinmann, Arndt and Galle, Peter R and Bettinger, Dominik and Bengsch, Bertram and Vogel, Arndt and Balcar, Lorenz and Scheiner, Bernhard and Lee, Pei-Chang and Huang, Yi-Hsiang and Amara, Suneetha and Muzaffar, Mahvish and Naqash, Abdul Rafeh and Cammarota, Antonella and Zanuso, Valentina and Pressiani, Tiziana and Pinter, Matthias and Cortellini, Alessio and Kudo, Masatoshi and Rimassa, Lorenza and Pinato, David J and Sharma, Rohini},
title = {Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma},
journal = {Hepatology International},
year = {2023},
doi = {10.1007/s12072-023-10491-3}
}
EUVIMED